Eli Lilly and Company (NYSE:LLY) Stake Boosted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Eli Lilly and Company (NYSE:LLY) by 5.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,581,075 shares of the company’s stock after purchasing an additional 171,595 shares during the period. Eli Lilly and Company comprises 0.8% of Dimensional Fund Advisors LP’s investment portfolio, making the stock its 8th largest position. Dimensional Fund Advisors LP owned 0.38% of Eli Lilly and Company worth $3,242,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of LLY. AMJ Financial Wealth Management purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $201,000. Aveo Capital Partners LLC increased its stake in Eli Lilly and Company by 8.2% in the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after purchasing an additional 153 shares during the period. Gryphon Financial Partners LLC increased its stake in Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 377 shares during the period. Main Street Financial Solutions LLC increased its stake in shares of Eli Lilly and Company by 2.5% during the fourth quarter. Main Street Financial Solutions LLC now owns 876 shares of the company’s stock valued at $511,000 after buying an additional 21 shares during the period. Finally, Motco increased its stake in shares of Eli Lilly and Company by 270.8% during the fourth quarter. Motco now owns 9,219 shares of the company’s stock valued at $5,374,000 after buying an additional 6,733 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.2 %

Eli Lilly and Company stock opened at $923.71 on Monday. The stock has a market cap of $877.92 billion, a PE ratio of 136.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The stock has a fifty day moving average of $897.12 and a 200 day moving average of $833.89.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analyst Ratings Changes

Several research firms recently weighed in on LLY. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Guggenheim boosted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $977.35.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 451,900 shares of company stock worth $418,732,178. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.